Clinical trial • Phase I/II • Oncology
CAPECITABINE for Breast cancer | Metastatic breast cancer
Phase I/II trial of CAPECITABINE for Breast cancer | Metastatic breast cancer. Randomised, open-label, adaptive. 44 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Breast cancer | Metastatic breast cancer
- Trial Stage
- Phase I/II
- Drug Modality
- Radiopharmaceutical | Small molecule
- Orphan Drug
- Yes
Key dates
- Initial CTIS Submission Date
- 13-12-2023
- First CTIS Authorization Date
- 23-04-2024
Trial design
Randomised, open-label, adaptive Phase I/II trial in Italy, Germany, Spain and others.
- Randomised
- Yes
- Open Label
- Yes
- Adaptive
- True - Phase I includes dose-escalation to determine Recommended Doses (RD) and dosing regimens; Phase II evaluates preliminary anti-tumor activity across two randomized cohorts of two different doses/regimens to optimize dosing. Specific escalation rules and stopping rules not provided in CTIS summary.
- Biomarker Stratified
- True, biomarker: GRPR status assessed by [68Ga]Ga-NeoB PET uptake (requirement: uptake above liver in target lesions); strata not specified
- Single Multiple Or Escalation Dose Combined
- Yes
- Target Sample Size
- 44
Eligibility
Recruits 44 Vulnerable population flag selected in CTIS. However the protocol inclusion criteria restrict participation to adults ≥18 years. Informed consent is required from adult participants (adult main ICF documents provided). Country-specific ICFs and information sheets are provided (multiple languages). A Child Assent document exists among the submission documents (France), and there are follow-up and partner information sheets for pregnant participants/partners, but children are not eligible per inclusion criteria. Consent/assent handling: adult participants provide informed consent using country/language-specific ICFs; additional informational documents for female partners, pregnancy follow-up and (where present) child assent templates are provided for regulatory completeness..
- Pregnancy Exclusion
- For Phase II part only · Pregnant or breast-feeding women · Women of childbearing potential (defined as all women physiologically capable of becoming pregnant) UNLESS they are using highly effective methods of contraception throughout the study and for up to 7 months after the last administration of [177Lu]Lu-NeoB or 6 months after the last dose of capecitabine (or as per locally prescribing information) whichever is longer.
- Vulnerable Population
- Vulnerable population flag selected in CTIS. However the protocol inclusion criteria restrict participation to adults ≥18 years. Informed consent is required from adult participants (adult main ICF documents provided). Country-specific ICFs and information sheets are provided (multiple languages). A Child Assent document exists among the submission documents (France), and there are follow-up and partner information sheets for pregnant participants/partners, but children are not eligible per inclusion criteria. Consent/assent handling: adult participants provide informed consent using country/language-specific ICFs; additional informational documents for female partners, pregnancy follow-up and (where present) child assent templates are provided for regulatory completeness.
Inclusion criteria
- {"criterion_text":"- Participant is female or male adult ≥ 18 years old at the time of informed consent(s)\n- For Phase I part and stand alone Japanese cohort only: Female participant must be in postmenopausal status at the time of starting study treatment, as defined in Section 5.1 Male participants, provided that they do not require continued GnRHas while on study treatment For Phase II part only Female participant is post-menopausal as per criteria above at the time of starting study treatment. Female participant is pre/peri-menopausal at the time of starting study treatment, as defined in Section 5.1 Male participants, regardless of their need of GnRHas while on study treatment.\n- Participant has a histologically and/or cytologically documented diagnosis of ER+ breast cancer (ER expression >10% of tumor cell nuclei stain (regardless of PgR expression) (based on the most recently analyzed tissue sample tested by a local laboratory).\n- Participant has HER2- breast cancer defined as a negative in situ hybridization test (ISH) or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative ISH (e.g., FISH, CISH, or SISH) (based on the most recently analyzed tissue sample tested by a local laboratory) is required.\n- Participant received no more than three prior endocrine therapy/ies (single agent or in combination with targeted therapy) regimen/s in the metastatic setting of which at least one included endocrine therapy in combination with a CDK4/6i. In addition: - In case of confirmed presence of deleterious or suspected deleterious germline BRCA1 or BRCA2 mutation, the participant may also have received a PARP inhibitor-based therapy. - In case of HER2-low breast cancer, the participant may also have received Enhertu®. Note: disease progression while on adjuvant ET (with or without CDK4/6i) or within 12 months of completing adjuvant endocrine therapy (with or without CDK4/6i), will be considered a line of therapy.\n- Participant has metastatic breast cancer with radiologically confirmed progression of disease after the most recent therapy\n- Participant must have measurable disease, i.e., at least one measurable lesion as per RECIST 1.1. (a lesion at a previously irradiated site may only be counted as a target lesion if there is a clear sign of progression since the irradiation) as per local assessment. Note: If only lytic bone lesions are present, they must have at least one lesion with a soft tissue component that can be evaluated by CT or MRI and meets the definition of measurability as per RECIST 1.1 criteria (participants with only one predominantly lytic bone lesion that has been previously irradiated are eligible if there is documented evidence of disease progression of the bone lesion after irradiation).\n- Participant has at least one target lesion [as per RECIST 1.1 and based on the baseline contrast-enhanced CT (or MRI)] with [68Ga]Ga-NeoB uptake above the liver at PET/CT or PET/MRI, as per local reading. In addition: Participant with liver or lung disease involvement must show [68Ga]Ga-NeoB uptake above the liver as follows: If there is liver disease involvement (in the absence of lung involvement), in ≥ 50% of all CT measurable liver lesions (RECIST 1.1) If there is lung disease involvement (in the absence of liver involvement), in ≥ 50% of all CT measurable lung lesions (RECIST 1.1) Participants with both liver and lung disease involvement must show [68Ga]Ga-NeoB uptake above the liver in ≥ 50% of all CT measurable lesions either in liver or lung (RECIST 1.1) and in at least one measurable lesion in the remaining organ (lung or liver)\n- Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n- Participant has adequate bone marrow and organ function as defined by laboratory values in section 5.1 (as assessed by local laboratory)."}
Exclusion criteria
- {"criterion_text":"- Participant with symptomatic visceral disease or any disease burden that are at risk of life-threatening complications as per the investigator’s judgment.\n- Sexually active male participants unwilling to: remain abstinent (refrain from sexual intercourse) or use a condom, while taking study treatment and for at least 4 months after the last administration of [177Lu]Lu-NeoB, or 3 months after the last dose of capecitabine (or as per locally prescribing information) whichever is longer, in addition to the highly effective method used by the partner who is a female of child-bearing potential.\n- For Phase II part only ·\tPregnant or breast-feeding women ·\tWomen of childbearing potential (defined as all women physiologically capable of becoming pregnant) UNLESS they are using highly effective methods of contraception throughout the study and for up to 7 months after the last administration of [177Lu]Lu-NeoB or 6 months after the last dose of capecitabine (or as per locally prescribing information) whichever is longer.\n- Participant has received >1 prior treatment with chemotherapy and/or Antibody Drug Conjugate (ADCs) in the metastatic setting. Chemotherapy in neoadjuvant/ adjuvant setting is not considered a line of therapy, unless progression or recurrence occurred during or within 12 months after completion of adjuvant chemotherapy).\n- Participant has received prior treatment with capecitabine\n- Participant has inflammatory breast cancer at screening.\n- Participant has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s judgment, cause unacceptable safety risks, contraindicate participant participation in the clinical study or compromise compliance with the protocol\n- History or current diagnosis of impaired cardiac function, clinically significant cardiac disease or ECG abnormalities\n- Participant is currently receiving brivudine which cannot be discontinued at least 4-week prior to start of capecitabine therapy.\n- Participant is currently receiving NEP inhibitors (i.e., Entresto®) and images for dosimetry assessments cannot be acquired for this participant as per Section 8.7.3 of the protocol.\n- Participant with known deficiency or family history of deficiency of dihydropyrimidine dehydrogenase."}
Endpoints
Primary endpoints
- {"endpoint_text":"- Phase I: Incidence and severity of AEs including dose limiting toxicities (DLTs), serious Adverse Events (SAEs), changes in laboratory parameters, vital signs and ECGs Tolerability: Dose interruptions, discontinuations, and reductions Phase II: ORR, CBR, TTR, DOR, PFS as per RECIST v1.1 by local investigator assessment Overall Survival (OS)","definition_or_measurement_approach":"Phase I safety endpoints assessed by incidence and severity of AEs (including DLTs, SAEs), laboratory parameters, vital signs and ECGs; tolerability assessed by dose interruptions, discontinuations and reductions. Phase II efficacy endpoints (ORR, CBR, TTR, DOR, PFS) assessed as per RECIST v1.1 by local investigator assessment; Overall Survival (OS) measured as time from randomization/first treatment to death."}
Secondary endpoints
- {"endpoint_text":"- Phase I and II: ● Time activity curves (TACs) and absorbed radiation doses of [177Lu]Lu-NeoB in organs and tumor lesions ● Concentration of [177Lu]Lu-NeoB in blood over time and derived PK parameters","definition_or_measurement_approach":"Dosimetry: time-activity curves and absorbed radiation doses in organs and tumor lesions; PK: blood concentration over time and derived pharmacokinetic parameters."}
- {"endpoint_text":"- Phase I and II: ● Incidence and severity of adverse events following [68Ga]Ga-NeoB administration at screening","definition_or_measurement_approach":"Safety monitoring of adverse events following [68Ga]Ga-NeoB administration at screening; incidence and severity captured per standard AE/SAE reporting."}
- {"endpoint_text":"- Phase I and II: ● Positive Percent Agreement (PPA) and Positive Predictive Agreement (PPrA) using conventional imaging as reference by central assessment, at screening","definition_or_measurement_approach":"Diagnostic concordance between [68Ga]Ga-NeoB PET and conventional imaging assessed centrally using PPA and PPrA metrics at screening."}
- {"endpoint_text":"- Phase I only: ● Visual assessment of image quality by central assessment","definition_or_measurement_approach":"Central visual assessment of image quality for Phase I imaging evaluations."}
- {"endpoint_text":"- Phase I only: ● ORR, CBR, TTR, DOR, PFS as per RECIST v1.1 by local investigator assessment ● OS","definition_or_measurement_approach":"Efficacy endpoints per RECIST v1.1 by local investigator assessment; OS measured as survival time."}
- {"endpoint_text":"- Phase II only: ● Incidence and severity of AEs, SAEs, changes in laboratory parameters, vital signs and ECGs Dose interruptions, discontinuations, and reductions","definition_or_measurement_approach":"Safety and tolerability assessments in Phase II by standard AE/SAE reporting and recording of dose modifications."}
Recruitment
- Registry Or Advocacy Recruitment
- True, Fundacion General De La Universidad De Malaga (Patient organisation/association) is listed as a third party involved in sponsor duties
- Planned Sample Size
- 44
- Recruitment Window Months
- 86
- Consent Approach
- Informed consent obtained from adult participants using country- and language-specific ICFs (Main ICF - Adult documents provided per country). Documents include ICFs and information sheets for adult participants, follow-up ICFs for pregnant participants/partners, and information sheets for female partners. Languages and country-specific ICFs present include Italian, German, Spanish, French, Portuguese, Dutch and Polish (and English patient-facing summaries). A Child Assent template is present among submission documents (France) though children are excluded by inclusion criteria. Separate data protection consent forms and optional assessments/addenda are included where applicable.
Methods
- Country-specific recruitment arrangements documented (K1 submissions exist for Italy, Germany, Spain, France, Portugal, Netherlands) - implies local recruitment processes per country.
- Advertisements (K2 documents) - country/language specific advertisement materials were submitted (examples: Italy - Italian; Germany - German; Spain - Spanish; France - French; Portugal - Portuguese; Netherlands - Dutch).
- Patient Recruitment Materials provided by Jumo Health USA Inc. (listed as third party with duty 'Patient Recruitment Materials').
Geography
- Total Number Of Sites
- 17
- Total Number Of Participants
- 40
Italy
- Earliest CTIS Part Ii Submission Date
- 12-01-2024
- Latest Decision Or Authorization Date
- 23-04-2024
- Processing Time Days
- 102
- Number Of Sites
- 2
- Number Of Participants
- 5
Sites
- Site Name
- Azienda USL IRCCS Di Reggio Emilia
- Department Name
- 4202: Oncology and High Technology Department, Nuclear Medicine Unit
- Principal Investigator Name
- Angelina Filice
- Principal Investigator Email
- angelina.filice@ausl.re.it
- Contact Person Name
- Angelina Filice
- Contact Person Email
- angelina.filice@ausl.re.it
- Number Of Participants
- 5
- Site Name
- Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
- Department Name
- 4201: Nuclear Medicine
- Principal Investigator Name
- Federica Matteucci
- Principal Investigator Email
- federica.matteucci@irst.emr.it
- Contact Person Name
- Federica Matteucci
- Contact Person Email
- federica.matteucci@irst.emr.it
Germany
- Earliest CTIS Part Ii Submission Date
- 11-03-2024
- Latest Decision Or Authorization Date
- 23-04-2024
- Processing Time Days
- 43
- Number Of Sites
- 4
- Number Of Participants
- 8
Sites
- Site Name
- Universitaetsklinikum Essen AöR
- Department Name
- 4101:Klinik fuer Nuklearmedizin
- Principal Investigator Name
- Ken Herrmann
- Principal Investigator Email
- Ken.herrmann@uk-essen.de
- Contact Person Name
- Ken Herrmann
- Contact Person Email
- Ken.herrmann@uk-essen.de
- Site Name
- Universitaetsklinikum Erlangen AöR
- Department Name
- 4103:Frauenklinik mit Poliklinik
- Principal Investigator Name
- Peter Fasching
- Principal Investigator Email
- peter.fasching.studien@uk-erlangen.de
- Contact Person Name
- Peter Fasching
- Contact Person Email
- peter.fasching.studien@uk-erlangen.de
- Site Name
- Universitaetsklinikum Tuebingen AöR
- Department Name
- 4104:Nuklearmedizin und Klinische Molekulare Bildgebung
- Principal Investigator Name
- Christian Lafougère
- Principal Investigator Email
- christian.lafougere@med.uni-tuebingen.de
- Contact Person Name
- Christian Lafougère
- Contact Person Email
- christian.lafougere@med.uni-tuebingen.de
- Site Name
- Klinikum rechts der Isar der TU Muenchen AöR
- Department Name
- 4102:Klinik und Poliklinik für Nuklearmedizin
- Principal Investigator Name
- Matthias Eiber
- Principal Investigator Email
- matthias.eiber@tum.de
- Contact Person Name
- Matthias Eiber
- Contact Person Email
- matthias.eiber@tum.de
- Number Of Participants
- 8
Spain
- Earliest CTIS Part Ii Submission Date
- 19-02-2024
- Latest Decision Or Authorization Date
- 23-04-2024
- Processing Time Days
- 64
- Number Of Sites
- 4
- Number Of Participants
- 13
Sites
- Site Name
- Hospital Universitario 12 De Octubre
- Department Name
- 4503:Servicio Oncología
- Principal Investigator Name
- Manuel Alva Bianchi
- Principal Investigator Email
- manuel.alva@salud.madrid.org
- Contact Person Name
- Manuel Alva Bianchi
- Contact Person Email
- manuel.alva@salud.madrid.org
- Site Name
- Hospital Clinic De Barcelona
- Department Name
- 4501:Servicio Oncología
- Principal Investigator Name
- Maria Jesús Vidal Losada
- Principal Investigator Email
- mjvidal@clinic.cat
- Contact Person Name
- Maria Jesús Vidal Losada
- Contact Person Email
- mjvidal@clinic.cat
- Site Name
- University Hospital Virgen Del Rocio S.L.
- Department Name
- 4504:Servicio Oncología
- Principal Investigator Name
- Marta Benavent Viñuales
- Principal Investigator Email
- marta.benavent.sspa@juntadeandalucia.es
- Contact Person Name
- Marta Benavent Viñuales
- Contact Person Email
- marta.benavent.sspa@juntadeandalucia.es
- Site Name
- Institut Catala D'oncologia
- Department Name
- 4502:Servicio Oncología
- Principal Investigator Name
- Rafael Villanueva Vazquez
- Principal Investigator Email
- ravillanueva@iconcologia.net
- Contact Person Name
- Rafael Villanueva Vazquez
- Contact Person Email
- ravillanueva@iconcologia.net
- Number Of Participants
- 13
France
- Earliest CTIS Part Ii Submission Date
- 05-03-2024
- Latest Decision Or Authorization Date
- 29-04-2024
- Processing Time Days
- 55
- Number Of Sites
- 5
- Number Of Participants
- 8
Sites
- Site Name
- Centre Hospitalier Universitaire Grenoble Alpes
- Department Name
- 4004: Medecine Nucleaire
- Principal Investigator Name
- Loic DJAILEB
- Principal Investigator Email
- ldjaileb@chu-grenoble.fr
- Contact Person Name
- Loic DJAILEB
- Contact Person Email
- ldjaileb@chu-grenoble.fr
- Site Name
- Centre Regional Lutte Contre Le Cancer
- Department Name
- 4005: Oncologie medicale
- Principal Investigator Name
- Laura BENDER-SOMME
- Principal Investigator Email
- l.bender@icans.eu
- Contact Person Name
- Laura BENDER-SOMME
- Contact Person Email
- l.bender@icans.eu
- Site Name
- Institut Gustave Roussy
- Department Name
- 4007: Medecine Nucleaire
- Principal Investigator Name
- Desiree DEANDREIS
- Principal Investigator Email
- desiree.deandreis@gustaveroussy.fr
- Contact Person Name
- Desiree DEANDREIS
- Contact Person Email
- desiree.deandreis@gustaveroussy.fr
- Site Name
- Institut De Cancerologie De L Ouest
- Department Name
- 4001: Oncologie
- Principal Investigator Name
- Mario CAMPONE
- Principal Investigator Email
- Mario.campone@ico.unicancer.fr
- Contact Person Name
- Mario CAMPONE
- Contact Person Email
- Mario.campone@ico.unicancer.fr
- Site Name
- Institut Bergonie
- Department Name
- 4006: Medecine Nucleaire
- Principal Investigator Name
- Paul SCHWARTZ
- Principal Investigator Email
- p.schwartz@bordeaux.unicancer.fr
- Contact Person Name
- Paul SCHWARTZ
- Contact Person Email
- p.schwartz@bordeaux.unicancer.fr
- Number Of Participants
- 8
Portugal
- Earliest CTIS Part Ii Submission Date
- 04-04-2024
- Latest Decision Or Authorization Date
- 26-04-2024
- Processing Time Days
- 22
- Number Of Sites
- 1
- Number Of Participants
- 3
Sites
- Site Name
- Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E.
- Department Name
- 4401: Serviço de Oncologia Médica
- Principal Investigator Name
- Ana Ferreira
- Principal Investigator Email
- Ana.magalhaes.ferreira@ipoporto.min-saude.pt
- Contact Person Name
- Ana Ferreira
- Contact Person Email
- Ana.magalhaes.ferreira@ipoporto.min-saude.pt
- Number Of Participants
- 3
Netherlands
- Earliest CTIS Part Ii Submission Date
- 12-04-2024
- Latest Decision Or Authorization Date
- 23-04-2024
- Processing Time Days
- 11
- Number Of Sites
- 1
- Number Of Participants
- 3
Sites
- Site Name
- Reinier de Graaf Groep
- Department Name
- 4301: Oncology
- Principal Investigator Name
- Lemonitsa Mammatas
- Principal Investigator Email
- l.mammatas@rdgg.nl
- Contact Person Name
- Lemonitsa Mammatas
- Contact Person Email
- l.mammatas@rdgg.nl
- Number Of Participants
- 3
Sponsor
Primary sponsor
- Full Name
- Novartis Pharma AG
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Switzerland
Contract research organisations
- Name
- Parexel International (IRL) Limited
- Responsibilities
- Role code 12 (clinical operations/monitoring functions as indicated in sponsor duties)
- Name
- Syneos Health Inc.
- Responsibilities
- Clinical operations support (sponsor duties code 1)
- Name
- Icon Clinical Research Limited
- Responsibilities
- Clinical operations support (sponsor duties code 1)
- Name
- IQVIA Limited / Iqvia Rds Inc.
- Responsibilities
- Randomization, management of drug supply logistics, dispensing, unblinding, ECG analysis and other trial support functions
Third parties
- {"country":"United States","full_name":"Medidata Solutions Inc.","duties_or_roles":"Database management and quality control","organisation_type":"Non-Pharmaceutical company"}
- {"country":"United Kingdom","full_name":"Charles River Laboratories Edinburgh Limited","duties_or_roles":"Pharmacokinetics HPLC","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Invicro LLC","duties_or_roles":"Imaging for Dosimetry and Response Assessments","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Iqvia Rds Inc.","duties_or_roles":"Management of drug supply logistics, dispensing, and unblinding. Randomization of patients.","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Syneos Health Inc.","duties_or_roles":"Services (sponsor duties code: 1)","organisation_type":"Pharmaceutical company"}
- {"country":"Spain","full_name":"Advanced Accelerator Applications Iberica S.L.","duties_or_roles":"Role code 14 (specific duty text provided in sponsor documentation)","organisation_type":"Pharmaceutical company"}
- {"country":"Ireland","full_name":"Parexel International (IRL) Limited","duties_or_roles":"Role code 12","organisation_type":"Pharmaceutical company"}
- {"country":"Spain","full_name":"Fundacion General De La Universidad De Malaga","duties_or_roles":"Role code 14 (patient organisation involvement)","organisation_type":"Patient organisation/association"}
- {"country":"Ireland","full_name":"Icon Clinical Research Limited","duties_or_roles":"Role code 1","organisation_type":"Pharmaceutical company"}
- {"country":"Netherlands","full_name":"Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)","duties_or_roles":"Role code 14 (trial pharmacy role)","organisation_type":"Hospital/Clinic/Other health care facility"}
- {"country":"United States","full_name":"Labcorp Central Laboratory Services LP","duties_or_roles":"Sample storage; provision of sample collection kits","organisation_type":"Pharmaceutical company"}
- {"country":"Spain","full_name":"Advanced Accelerator Applications Molecular Imaging Iberica S.L.","duties_or_roles":"Role code 14","organisation_type":"Pharmaceutical company"}
- {"country":"Portugal","full_name":"Advanced Accelerator Applications (Portugal) Unipessoal Lda.","duties_or_roles":"Central RadioPharmacy","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"RWS Life Sciences Inc.","duties_or_roles":"Electronic Patient Reported Outcomes (ePRO) formatting, translations, and licensing","organisation_type":"Pharmaceutical company"}
- {"country":"United Kingdom","full_name":"IQVIA Limited","duties_or_roles":"Clinical trial services including ECG analysis and other CRO services","organisation_type":"Pharmaceutical company"}
- {"country":"France","full_name":"Creapharm Clinical Supplies","duties_or_roles":"Drug distribution, storage, relabeling, return and destruction","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Jumo Health USA Inc.","duties_or_roles":"Patient Recruitment Materials","organisation_type":"Hospital/Clinic/Other health care facility"}
- {"country":"Germany","full_name":"Saale-Apotheke Dr. Christian Wegner e.Kfm.","duties_or_roles":"Role code 14 (radio pharmacy role)","organisation_type":"Hospital/Clinic/Other health care facility"}
- {"country":"United States","full_name":"Bbk Worldwide LLC","duties_or_roles":"Patient Reimbursement for Germany","organisation_type":"Pharmaceutical company"}
- {"country":"France","full_name":"Kayentis","duties_or_roles":"Coordination of licensing, translation and development of electronic patient reported outcomes (PROs). Data capture and cleaning of completed PROs.","organisation_type":"Non-Pharmaceutical company"}
- {"country":"United States","full_name":"RWS Life Sciences Inc.","duties_or_roles":"ePRO formatting/translations (duplicate entry consolidated)","organisation_type":"Pharmaceutical company"}
- {"country":"Spain","full_name":"Advanced Accelerator Applications Iberica S.L. (Molecular Imaging)","duties_or_roles":"Role code 14 (radiopharmacy/imaging support)","organisation_type":"Pharmaceutical company"}
Investigational products
- Investigational Product Name
- CAPECITABINE
- Active Substance
- CAPECITABINE
- Modality
- Small molecule
- Routes Of Administration
- ORAL
- Route
- ORAL
- Authorisation Status
- prodAuthStatus:2
- Investigational Product Name
- [177Lu]-NeoB solution for infusion
- Active Substance
- LUTETIUM (177LU)-NEOBOMB1
- Modality
- Radiopharmaceutical
- Routes Of Administration
- INTRAVENOUS USE
- Route
- INTRAVENOUS
- Authorisation Status
- prodAuthStatus:1
- Investigational Product Name
- AAA503
- Active Substance
- NEOB
- Modality
- Radiopharmaceutical (kit for radiopharmaceutical preparation)
- Routes Of Administration
- INTRAVENOUS USE
- Route
- INTRAVENOUS
- Authorisation Status
- prodAuthStatus:1
- Orphan Designation
- Yes
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)